[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-381585-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-381585-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","crispr-applications-in-cancer-diagnosis-and-treatment","CRISPR applications in cancer diagnosis and treatment","","Cancer remains a significant global health challenge, driving the search for more precise therapeutic options beyond conventional surgery, chemotherapy, and radiation. CRISPR systems have emerged as promising tools for clinical gene editing because CRISPR-associated proteins recognize specific target sequences. This review summarizes key functional features of Cas9, Cas12, and Cas13, including Cas9 cis-cleavage and Cas12/Cas13 trans-cleavage for cancer diagnostics. It highlights current advances and stresses balancing strengths and limitations to maximize clinical utility and guide future innovation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/crispr-applications-in-cancer-diagnosis-and-treatment/381585/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/crispr-applications-in-cancer-diagnosis-and-treatment/381585.png","ImageObject",300,407,{"name":42,"@type":43},"Rizky","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What makes CRISPR systems promising for cancer diagnosis and treatment?","Question",{"text":63,"@type":64},"CRISPR-associated proteins can recognize specific target sequences, enabling clinical gene editing and supporting diagnostic applications. The review also distinguishes different cleavage behaviors that broaden CRISPR use.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do Cas9, Cas12, and Cas13 differ in their cleavage activities?",{"text":68,"@type":64},"Cas9 guides precise double-stranded DNA cleavage using a single-guide RNA. Cas12 and Cas13 introduce trans-cleavage activity, expanding their diagnostic and cancer-related applications.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is understanding the strengths and limitations of each CRISPR system important?",{"text":72,"@type":64},"The document emphasizes that clinical utility depends on matching each system’s capabilities and constraints to the intended cancer gene therapy or molecular diagnosis purpose.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},381585,1790294257,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146},962085564807,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Wang et al.  \nCellular & Molecular Biology Letters (2023) 28:73 [https://doi.org/10.1186/s11658-023-00483-4](https://doi.org/10.1186/s11658-023-00483-4)  \nCellular & Molecular Biology Letters  \nREVIEW LETTER Open Access  \nCRISPR applications in cancer diagnosis and treatment  \nMingxia Wang1,2†, Menghui Chen1†, Xia Wu1, Xinbo Huang1* and BoYu1*  \n\n| †Mingxia Wang and Menghui Chen contributed equally to this work and considered as co-first authors. |\n| --- |\n| *Correspondence:\u003Cbr>[huangxinbo92@pku.edu.cn](huangxinbo92@pku.edu.cn); [drboyu_derm@126.com](drboyu_derm@126.com) |\n\n1 Department of Dermatology, Skin Research Institute of Peking University Shenzhen Hospital, Peking University Shenzhen Hospital, Shenzhen 518036, China  \n2 Shenzhen Key Laboratory of Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen 518000, China  \nAbstract  \nCancer remains a significant global health challenge, necessitating the exploration of novel and more precise therapeutic options beyond conventional treatments. In this regard, clustered regularly interspaced short palindromic repeats (CRISPR) systems have emerged as highly promising tools for clinical gene editing applications. The CRISPR family encompasses diverse CRISPR-associated (Cas) proteins that possess the ability to recognize specific target sequences. The initial CRISPR system consisted of the Cas9 protein and a single-guide RNA, which guide Cas9 to the desired target sequence, facilitating precise double-stranded cleavage. In addition to the traditional cis-cleavage activity, the more recently discovered Cas12 and Cas13 proteins exhibit trans-cleavage activity, which expands their potential applications in cancer diagnosis. In this review, we provide an overview of the functional characteristics of Cas9, Cas12, and Cas13 . Furthermore, we highlight the latest advancements and applications of these  \nCRISPR systems in cancer gene therapy and molecular diagnosis. We also emphasize the importance of understanding the strengths and limitations of each CRISPR system to maximize their clinical utility. By providing a comprehensive overview of the current state of CRISPR technology in cancer research, we aim to inspire further exploration and innovation in this rapidly evolving field.  \nKeywords: Cas9, Cas12, Cas13, Cancer, Gene therapy, Diagnostic tools, Clinical trials  \n© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://](http://)[ ](http://)[creativecommons.org/licenses/by/4.0/](creativecommons.org/licenses/by/4.0/.)[.](creativecommons.org/licenses/by/4.0/.)  \nWang et al. Cellular & Molecular Biology Letters (2023) 28:73 Page 2 of 22  \nGraphical abstract  \nIntroduction  \nCancer, characterized by an unrestrained and invasive proliferation of abnormal cells [1], has long been the leading cause of death worldwide and remained a vital public health concern [2] ([https://gco.iarc.fr/today/fact-sheets-cancers](https://gco.iarc.fr/today/fact-sheets-cancers)). Despite being the cornerstone of cancer treatment, traditional therapies such as surgery [3], chemotherapy [4], and radiation therapy [5] have limitations including lack of specificity, significant side effects, and chal","cbCaitqiuCSzn4N1","https://ap.wps.com/l/cbCaitqiuCSzn4N1","pdf",2052654,22,"English","# Introduction\n## Cancer treatment limitations and the need for precision\n## Gene therapy and the role of CRISPR\n# CRISPR biology and system classification\n## Discovery timeline from CRISPR to Cas9\n## Classes and types of CRISPR-Cas systems","[{\"question\":\"What makes CRISPR systems promising for cancer diagnosis and treatment?\",\"answer\":\"CRISPR-associated proteins can recognize specific target sequences, enabling clinical gene editing and supporting diagnostic applications. The review also distinguishes different cleavage behaviors that broaden CRISPR use.\"},{\"question\":\"How do Cas9, Cas12, and Cas13 differ in their cleavage activities?\",\"answer\":\"Cas9 guides precise double-stranded DNA cleavage using a single-guide RNA. Cas12 and Cas13 introduce trans-cleavage activity, expanding their diagnostic and cancer-related applications.\"},{\"question\":\"Why is understanding the strengths and limitations of each CRISPR system important?\",\"answer\":\"The document emphasizes that clinical utility depends on matching each system’s capabilities and constraints to the intended cancer gene therapy or molecular diagnosis purpose.\"}]","CRISPR applications in cancer diagnosis and treatment | PDF",1790246090,55]